BLUEPRINT MEDICINES CORP (BPMC)

Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024

/PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on...

Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics

/PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced it will launch a webcast series to provide scientific perspectives and showcase...

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective April 1, 2024, the Compensation Committee of Blueprint...

Blueprint Medicines Larger Than S&P 500 Component VFC

First Week of May 17th Options Trading For Blueprint Medicines (BPMC)

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective March 1, 2024, the Compensation Committee of Blueprint...

Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting

-- AYVAKIT data in patients with indolent systemic mastocytosis show durable efficacy and favorable safety supporting long-term treatment, consistent with...

Blueprint Medicines Outranks 92% Of All Stocks. But This Could Be Its Undoing.

The company reported better-than-expected sales of its rare-disease drug, but there's one drawback in its report.

Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results

-- Achieved $204.2 million in AYVAKIT®/AYVAKYT® (avapritinib) net product revenues in 2023, including $71.0 million in the fourth quarter -- -- Anticipate...

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective February 1, 2024, the Compensation Committee of Blueprint...

Blueprint Medicines to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024

/PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on...

Barron’s cites cancer and weight loss plays for biotech M&A (NASDAQ:VKTX)

On the back of recent deals involving big pharma, Barron’s issued positive remarks on a possible acceleration of biotech M&A activity on Tuesday. Read more here.

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective January 1, 2023, the Compensation Committee of Blueprint...

Notable Tuesday Option Activity: ITOS, APPS, BPMC

Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis

/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced the European Commission has approved AYVAKYT® (avapritinib) for the treatment of...

Blueprint Medicines Moves Up In Market Cap Rank, Passing Sealed Air

Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted at 2023 ASH Annual Meeting

/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data showcasing its commitment to advance the scientific understanding and...

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective December 1, 2023, the Compensation Committee of Blueprint...

Commit To Buy Blueprint Medicines At $55, Earn 8% Using Options

Blueprint Medicines to Present at JMP Securities Hematology and Oncology Summit

/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that company management will participate virtually in a fireside chat at the JMP...

Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion as the First and Only Therapy for Indolent Systemic Mastocytosis

/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European...

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective November 1, 2023, the Compensation Committee of Blueprint...

Why Blueprint Medicines Stock Soared Today

The precision-treatment company saw stronger-than-expected sales in its first full quarter following the launch of Ayvakit.